NASTAD has created a sign-on letter for Congressional leaders and appropriators asking that they allocate at least $100 million to CDC’s viral hepatitis program in FY2018. Congress included $6 billion over two years included in the Bipartisan Budget Act of 2018 to fight the nation’s opioid epidemic and this letter urges a portion of that funding goes to communities to deal with increasing hepatitis C, hepatitis B and HIV infections. For more information about the ask please see the letter. If your organization would like to be included please fill out this google form by next Wednesday, February 21st.
The American Medical Association launched a website for consumers to tell their stories of how rising prices are affecting their health and their pocketbooks.
Advocacy, Federal Budget, Hepatitis B, Hepatitis C
It is essential to the health of all Americans that we capitalize on the opportunity to invest in viral hepatitis prevention, testing, linkage to care, and education programs and transform our public health system. In order to accomplish this, we must maintain the Prevention an...
Submit comments of support to the Centers for Medicare & Medicaid Services to have Medicare cover Hep B screening.
Advocacy, Hepatitis C, Petition
VOCAL-NY is launching this petition campaign to make sure that people know that we need to create a drug pricing system that can never been exploited again.
Advocacy, Awareness Days, News, Hepatitis B, Hepatitis C, World Hepatitis Day
Presidential Proclamation | World Hepatitis Day 2015 As President, I am committed to advancing the fight against viral hepatitis. The Affordable Care Act has increased access to quality, affordable health care. BY THE PRESIDENT OF THE UNITED STATES OF AMERICA Around the wo...
Advocacy, Federal Budget, Hepatitis C, Medicare, Sign On Letter
Sign the letter urging Secretary Sebelius to ensure that Medicare incorporates hepatitis C screening into the Welcome to Medicare exam and the Medicare annual wellness visit.
Advocacy, Funding, News
Urge your members of congress to sign on in support of increased funding for the Division of Viral Hepatitis at the Centers for Disease Control and Prevention (CDC) in FY2014. Members of Congress need to know that viral hepatitis is a concern in their district, that their constit...
Advocacy, HepCX News, News, Hepatitis C, Medicaid, Open for Comment, Pharmaceutical
On February 26th, the New York State Drug Utilization Review Board will meet to review and recommend NYS Medicaid clinical criteria for Viekira Pak - the most recently approved Hepatitis C therapy - marketed by AbbVie.